Thioredoxin-interacting protein (TXNIP) mRNA (TXNIP mRNA)

Thioredoxin-interacting protein (TXNIP) mRNA is the transcript for a key metabolic and redox regulator that plays a central role in the pathogenesis of diabetes and other oxidative stress-related disorders [Shalev, 2014]. The encoded TXNIP protein binds to and inhibits thioredoxin, a major antioxidant, thereby increasing cellular oxidative stress and triggering the NLRP3 inflammasome [Zhou et al., 2010]. In pancreatic beta-cells, TXNIP mRNA expression is strongly induced by high glucose levels, which leads to programmed cell death and the progression of both Type 1 and Type 2 diabetes [Shalev, 2014]. Therapeutic targeting of TXNIP mRNA aims to lower protein levels to preserve beta-cell mass and improve insulin sensitivity. This can be achieved through small molecules like verapamil, which has been shown to suppress TXNIP transcription and improve outcomes in clinical trials for recent-onset Type 1 diabetes [Ovalle et al., 2018]. Additionally, RNA-targeted approaches such as antisense oligonucleotides are being explored to specifically degrade TXNIP mRNA. While promising, the role of TXNIP as a tumor suppressor in various tissues necessitates a cautious approach to ensure that therapeutic downregulation does not inadvertently promote oncogenesis [Yoshihara et al., 2014].

Other names

Vitamin D3 up-regulated protein 1 mRNAVDUP1 mRNAThioredoxin-binding protein 2 mRNATBP-2 mRNA

Reduction of TXNIP protein expression through mRNA degradation or transcriptional inhibition